Contact this trialFirst, we need to learn more about you.
PD-1 Inhibitor
PD-1 Inhibitor vs. PD-1 + TIM-3 Inhibitors for Melanoma
Recruiting1 awardPhase 2
Washington, Pennsylvania
This trial tests Dostarlimab alone or with TSR-022 in patients with advanced but operable melanoma. These drugs help the immune system attack cancer by preventing cancer cells from hiding. The goal is to see if these treatments improve outcomes before and after surgery.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service